Hosted on MSN
Here's everything you need to know about lenacapavir, the newly approved HIV-prevention injection
The United States Food and Drug Administration has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new ...
In a major breakthrough in the fight against HIV, the US Food and Drug Administration (FDA) has approved lenacapavir, under the brand name Yeztugo, a long-acting injectable drug developed by Gilead ...
The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US. Cost could make lenacapavir ...
The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new treatment ...
The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...
The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...
An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug that offers 100% protection with its twice-yearly injections. It's a landmark ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo® (lenacapavir) 300-mg tablet as a ...
According to UNAIDS, in 2024, about 40.8 million people around the world were living with the human immunodeficiency virus (HIV) — a virus that can lead to acquired immunodeficiency syndrome (AIDS) if ...
Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with drug-resistant infections in 2022. While there is still no vaccine for the ...
– Gilead’s Research Presentations and Community Events at IAS Reflect Commitment to Partnerships in Developing Person-Centered Options for a Diverse Range of Populations – FOSTER CITY, ...
Gilead Sciences, Inc. (GILD) announced that the European Commission (“EC”) has granted marketing authorization to HIV prevention drug lenacapavir, under the brand name Yeytuo. The EC approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results